financetom
Business
financetom
/
Business
/
Glaukos Insider Sold Shares Worth $264,791, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Glaukos Insider Sold Shares Worth $264,791, According to a Recent SEC Filing
May 14, 2024 2:23 PM

04:47 PM EDT, 05/14/2024 (MT Newswires) -- Joseph E Gilliam, President & COO, on May 10, 2024, sold 2,395 shares in Glaukos ( GKOS ) for $264,791. Following the Form 4 filing with the SEC, Gilliam has control over a total of 101,845 shares of the company, with 101,845 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1192448/000141588924013136/xslF345X03/form4-05142024_080543.xml

Price: 110.02, Change: -0.95, Percent Change: -0.86

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
LyondellBasell, Covestro to permanently close Netherlands unit
LyondellBasell, Covestro to permanently close Netherlands unit
Mar 18, 2025
(Reuters) - LyondellBasell said on Tuesday the chemical firm and Covestro have decided to permanently close the Propylene Oxide Styrene and Monomer production unit at the Maasvlakte site in the Netherlands. ...
Full Circle Lithium, Japan's ITOCHU to Bring FCL Fire-Extinguishing Agent to Japan, Korea
Full Circle Lithium, Japan's ITOCHU to Bring FCL Fire-Extinguishing Agent to Japan, Korea
Mar 18, 2025
09:18 AM EDT, 03/18/2025 (MT Newswires) -- Full Circle Lithium ( FCLIF ) said Tuesday that it will collaborate with Japan's ITOCHU to bring Full Circle's FCL-X lithium-ion battery fire-extinguishing agent to Japanese and Korean markets. The companies aim to seal a final binding agreement after certain customary due-diligence items are confirmed. The agreement may be expanded into additional Asian...
Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient
Can-Fite Says US FDA Approves Compassionate Use Treatment With Namodenoson in Pancreatic Cancer Patient
Mar 18, 2025
09:23 AM EDT, 03/18/2025 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Tuesday that the US Food and Drug Administration has approved the compassionate use treatment with anti-cancer drug Namodenoson for a pancreatic cancer patient in the US. The clinical-stage company said it is currently evaluating Namodenoson in a late-stage clinical trial for advanced liver cancer, while it is...
Nasdaq to Open Regional Headquarters in Dallas
Nasdaq to Open Regional Headquarters in Dallas
Mar 18, 2025
09:19 AM EDT, 03/18/2025 (MT Newswires) -- Nasdaq (NDAQ) said Tuesday it plans to open a new regional headquarters in Dallas to serve clients in Texas and the Southeast region. The company said it intends to make additional investments in Texas to improve the liquidity, transparency, and integrity of the financial ecosystem. Nasdaq said it generated more than $750 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved